Learn everything you need to know about Febuxostat-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...

Am J Health Syst Pharm. 2011;68(5):389-398. As a xanthine oxidase inhibitor, febuxostat may interact with drugs that are metabolized by xanthine oxidase. Febuxostat is currently contraindicated in ...

Hyperuricemia is frequently observed among patient with chronic kidney disease. Febuxostat may offer superior renal-protective effects compared with allopurinol in patients with stage 3 chronic kidney ...

(UPDATED) Despite worries over a potential CV risk with febuxostat, there is indeed a population of patients with gout for whom the risk-benefit profile is favorable for the treatment of hyperuricemia ...

kidney illustration Study of patients with CKD stage 3 and asymptomatic hyperuricemia showed that febuoxostat ameliorated the annual decline in eGFR vs placebo in those without proteinuria. Febuxostat ...

Febuxostat is a xanthine oxidase (XO) inhibitor, prescribed for gout and hyperuricemia (high level of uric acid in blood). The serum concentration of the active metabolites of Ambroxol acefyllinate ...

Please provide your email address to receive an email when new articles are posted on . Risk of death from all causes was similarly lower for patients on hemodialysis prescribed either allopurinol or ...

Hyperuricemia in patients with gout is most commonly treated with allopurinol. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, could potentially be a therapeutic alternative for ...

Cardiovascular risk is increased in patients with gout. We compared cardiovascular outcomes associated with febuxostat, a nonpurine xanthine oxidase inhibitor, with those associated with allopurinol, ...

Tokyo, Japan, June 30, 2015 --- Teijin Pharma Limited, the core company of the Teijin Group's medical and pharmaceutical business, announced today, the Menarini Group, a sublicensee of its European ...

Febuxostat 40 mg daily appears to be as efficacious as allopurinol in lowering serum uric acid levels. [38] Both febuxostat 40 and 80 mg can be given to patients with mild-to-moderate renal impairment ...